←
James Murrough201 posts
James Murrough avatar

James Murrough

@JMurrough

Professor of Psychiatry & Neuroscience @MountSinaiNYC. Translational neuroscience, clinical trials & new treatments for mood and anxiety disorders.

◷ Joined April 2015▧ 3 Photos and videos
James Murrough avatar
James Murrough@JMurrough·14h

Very novel and important results! @cl9681 @immanuel_elbau

One of the coolest findings I’ve seen in human brain imaging. When @immanuel_elbau first showed me that ECT changed hippocampal connectivity in our densely-sampled patient (39 study visits over 6 months), I expected a familiar default mode network (DMN) pattern, just stronger or weaker.

James Murrough avatar
James Murrough@JMurrough·Nov 13

Thank you to all the Veterans who came out today for a conversation about #depression, its treatment, and research into its causes and new treatments at MIRECC and VA. @VeteransHealth

A day after Veterans Day, I'm honored to join Veterans at the Bronx VA this morning for a conversation about depression: how it's treated and where research is headed. Grateful to the MIRECC team and to all who served. 🇺🇸 @VABronx @VeteransHealth

James Murrough avatar
James Murrough@JMurrough·Nov 12

A day after Veterans Day, I'm honored to join Veterans at the Bronx VA this morning for a conversation about depression: how it's treated and where research is headed. Grateful to the MIRECC team and to all who served. 🇺🇸 @VABronx @VeteransHealth

You’re invited! A Talk for Veterans: A Conversation About Depression. Join Dr. James Murrough, MD, PhD, for an open conversation about depression, followed by time for questions and connection. Meet the MIRECC team and enjoy coffee and snacks.

Post attachment
Eric J. Nestler, MD, PhD avatar
⟳ James Murrough retweeted
Eric J. Nestler, MD, PhD@EricJNestler·Nov 11

I am incredibly proud of @IcahnMountSinai's faculty and trainees whose cutting-edge, impactful research brought Mount Sinai into the top 10 of NIH-funded institutions for the first time in FY26.

Post attachment
James Murrough avatar
James Murrough@JMurrough·Nov 10

Nice commentary on a key issue in psychiatric and medical clinical trial design. Functional unblinding and expectancy are not unique to psychedelics, but psychedelic-like drugs are particularly vulnerable to them.

A commentary published in JCP argues that blinding integrity is rarely assessed in trials of drugs with noticeable effects, citing a review in which only 30% of 112 psychedelic and ketamine trials assessed it, and recommends asking patients what they guessed, why, and when. JCP → psychiatrist.com/jcp/functio… #ClinicalTrials #Psychopharmacology #JCP

Post attachment
James Murrough avatar
James Murrough@JMurrough·Nov 7

Very timely article! I sometimes wonder: do any of my patients not engage with apps or other digital technology in their journey to relieve suffering and enhance wellness?

Wellness app or digital therapeutic? Your patients may not know the difference, but your treatment plan should. Dr. Sagar Parikh (University of Michigan) walks through a new consensus panel paper in The Journal of Clinical Psychiatry that covers: → What separates a digital therapeutic from a wellness app → Four consensus statements to guide use in everyday practice → Where digital therapeutics fit within stepped care for MDD → Practical guidance for bringing these tools into your clinic Read the full consensus report: f.mtr.cool/jy3ej9m617 #Psychiatry #Depression #MDD #DigitalTherapeutics #DigitalHealth #MentalHealth

1:07
Johns Hopkins Psychedelic Research Center avatar
⟳ James Murrough retweeted
Johns Hopkins Psychedelic Research Center@JHPsychedelics·Nov 6

Dr. Frederick Barrett (@FredBarrettPhD) remarks in an article with the New York Times on the potential of novel treatments such as psychedelics for brain diseases like CTE (Chronic Traumatic Encephalopathy). nytimes.com/2026/10/28/scien…

James Murrough avatar
James Murrough@JMurrough·Nov 7

On @MountSinaiNYC's The Vitals, I joined Veerle Bergink and Shilpa Taufique for a conversation about the state of mental health. Even as treatments improve, many people who need care still cannot get it. We also talked about stigma and what's changing in how we understand and treat depression and other psychiatric illnesses. Important discussion! youtube.com/watch?v=w0W1Q5wH…

DepressionBrief avatar
⟳ James Murrough retweeted
DepressionBrief@DepressionBrief·Nov 5

Older adults with mild cognitive impairment are often left out of ketamine trials. In this open-label pilot of 13 people, one infusion was tolerated and depression scores fell sharply at 24 hours, with gains lasting a month for some. The Mount Sinai team flags the need for a real randomized trial.

Johns Hopkins Psychedelic Research Center avatar
⟳ James Murrough retweeted
Johns Hopkins Psychedelic Research Center@JHPsychedelics·Nov 3

Dr. David Yaden spoke on a panel that brought together scientific, policy, and legal perspectives on psychedelic treatment at Yale Law School’s Solomon Center for Health Law and Policy, reviewing what the science can and cannot yet tell us, including how to weigh their risks and benefits. law.yale.edu/yls-today/news/…